Masakazu Goto1, Takahiro Yoshida2, Yota Yamamoto3, Yoshihito Furukita4, Seiya Inoue1, Satoshi Fujiwara4, Naoya Kawakita1, Takeshi Nishino1, Takuya Minato5, Yasuhiro Yuasa6, Hiromichi Yamai7, Hirokazu Takechi1, Junichi Seike1, Yoshimi Bando8, Akira Tangoku1. 1. Department of Thoracic, Endocrine Surgery and Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan. 2. Department of Thoracic, Endocrine Surgery and Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan. tyoshida1@tokushima-u.ac.jp. 3. Sainokuni Higashiomiya Medical Center, Saitama, Japan. 4. Kochi Health Sciences Center, Kochi, Japan. 5. Shikoku Medical Center for Children and Adults, Kagawa, Japan. 6. Tokushima Red Cross Hospital, Tokushima, Japan. 7. Kochi Red Cross Hospital, Kochi, Japan. 8. Department of Molecular and Environmental Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Abstract
BACKGROUND: Chemokines and their receptors are known to play important roles in the tumorigenesis of many malignancies. The chemokine CXCL12 and its receptors CXCR4 and CXCR7 were suggested to be involved in cancer invasion and metastasis. The aim of this retrospective study was to evaluate the prognostic impact of the expressions of CXCL12, CXCR4 and CXCR7 in patients with esophageal squamous cell carcinoma (ESCC). METHODS: We used immunohistochemistry (IHC) and reverse transcriptase-polymerase chain reaction (RT-PCR) to evaluate the expressions of CXCL12, CXCR4, and CXCR7 in ESCC patients' tumor biopsy specimens obtained during preoperative endoscopy or surgery. These results were compared with the patients' clinicopathological parameters and survival. RESULTS: IHC was conducted for 172 patients. High expression of CXCR4 in the cytoplasm and nuclei and that of CXCR7 were associated with poor cause-specific survival (CSS) (P= .002 and .010, respectively). The specimens from 52 of the 172 patients were examined by RT-PCR and quantitative real-time PCR. The expression levels of messenger RNA (mRNA) of CXCR4 and CXCR7 were significantly increased in the tumors compared with normal esophageal mucosae (P < .0001). The expression level of mRNA of CXCR4 was associated with poor recurrence-free survival and CSS (P = .012 and .038, respectively). CONCLUSIONS: CXCR4 expression is associated with poor prognosis in patients with ESCC.
BACKGROUND: Chemokines and their receptors are known to play important roles in the tumorigenesis of many malignancies. The chemokine CXCL12 and its receptors CXCR4 and CXCR7 were suggested to be involved in cancer invasion and metastasis. The aim of this retrospective study was to evaluate the prognostic impact of the expressions of CXCL12, CXCR4 and CXCR7 in patients with esophageal squamous cell carcinoma (ESCC). METHODS: We used immunohistochemistry (IHC) and reverse transcriptase-polymerase chain reaction (RT-PCR) to evaluate the expressions of CXCL12, CXCR4, and CXCR7 in ESCC patients' tumor biopsy specimens obtained during preoperative endoscopy or surgery. These results were compared with the patients' clinicopathological parameters and survival. RESULTS: IHC was conducted for 172 patients. High expression of CXCR4 in the cytoplasm and nuclei and that of CXCR7 were associated with poor cause-specific survival (CSS) (P= .002 and .010, respectively). The specimens from 52 of the 172 patients were examined by RT-PCR and quantitative real-time PCR. The expression levels of messenger RNA (mRNA) of CXCR4 and CXCR7 were significantly increased in the tumors compared with normal esophageal mucosae (P < .0001). The expression level of mRNA of CXCR4 was associated with poor recurrence-free survival and CSS (P = .012 and .038, respectively). CONCLUSIONS:CXCR4 expression is associated with poor prognosis in patients with ESCC.
Authors: Manol Jovani; Elizabeth E Liu; Samantha M Paniagua; Emily S Lau; Shawn X Li; Katherine S Takvorian; Bernard E Kreger; Greta Lee Splansky; Rudolf A de Boer; Amit D Joshi; Shih Jen Hwang; Chen Yao; Tianxiao Huan; Paul Courchesne; Martin G Larson; Daniel Levy; Andrew T Chan; Jennifer E Ho Journal: Cardiovasc Res Date: 2022-07-27 Impact factor: 13.081
Authors: Y Qiao; C Zhang; A Li; D Wang; Z Luo; Y Ping; B Zhou; S Liu; H Li; D Yue; Z Zhang; X Chen; Z Shen; J Lian; Y Li; S Wang; F Li; L Huang; L Wang; B Zhang; J Yu; Z Qin; Y Zhang Journal: Oncogene Date: 2017-10-23 Impact factor: 9.867
Authors: Lin Li; Grace Gar-Lee Yue; Julia Kin-Ming Lee; Eric Chun-Wai Wong; Kwok-Pui Fung; Jun Yu; Clara Bik-San Lau; Philip Wai-Yan Chiu Journal: Sci Rep Date: 2017-04-12 Impact factor: 4.379
Authors: Harsh Samarendra; Keaton Jones; Tatjana Petrinic; Michael A Silva; Srikanth Reddy; Zahir Soonawalla; Alex Gordon-Weeks Journal: Br J Cancer Date: 2017-05-23 Impact factor: 7.640
Authors: Anna Gójska-Grymajło; Maciej Zieliński; Dariusz Gąsecki; Kamil Kowalczyk; Mariusz Kwarciany; Barbara Seroczyńska; Walenty M Nyka Journal: Neuromolecular Med Date: 2018-05-09 Impact factor: 3.843